Company intelligence / Profile preview
TheraMAB
Chinatheramabs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TheraMAB developed theralizumab (TAB08/TGN1412), a humanized IgG4 monoclonal antibody targeting CD28 for autoimmune diseases and cancer. The drug was originally developed by TeGenero as TGN1412 but caused severe adverse events in its first-in-human trial in 2006. After TeGenero’s bankruptcy, rights were acquired by TheraMAB. Subsequent trials included Phase II for systemic lupus erythematosus and Phase I/II for plaque psoriasis; some trials were terminated due to administrative reasons or lack of progress. No recent clinical results are reported since 2021.
- Therapeutic areas
- DermatologyImmunologyOncology
- Modalities
- Monoclonal antibodyHumanized monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships reported post-acquisition from TeGenero
Beyond the preview
Go deeper on TheraMAB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheraMAB.